Departed
John Gandolfo
director
ODYY ·
Odyssey Health, Inc.
Effective October 5, 2023, John Gandolfo resigned as a director of Odyssey Health, Inc.
Ready 8-Ks
50
Latest filing
May 22, 2026, 7:07 PM ET
Top materiality
0.75
Event mix
debt ×21 · other_material ×21 · m_and_a ×5
Sentiment
12 pos · 3 neg · 35 neu
Executive change
recent →
Recent 8-K filings for ODYY
Highest-materiality recent filing
Odyssey Health closes asset sale of brain illness drug candidates to Oragenics for $1M cash and 8M preferred shares
- Sold drug candidates for mild traumatic brain injury and Niemann Pick Disease Type C, plus proprietary powder formulation and nasal delivery device.
- Received $1M in cash plus 8M shares of convertible Series F Preferred Stock from Oragenics.
-
Odyssey Health extends $1.05M convertible note maturity to Sept 30, 2026
Amendment No. 12 with LGH Investments extends maturity of $1.05M convertible note to September 30, 2026.
-
Odyssey Health's sublicense deal for BreastCheck cancelled by NeuRX due to breach of Davion contract
NeuRX revoked its Oct 2025 agreement with Odyssey to sublicense Davion's BreastCheck product, effective immediately.
-
Odyssey Health closes exclusive global distribution deal for BreastCheck non-invasive breast test
Closed sub-license with NeuRX Health granting subsidiary Odyssey Medical Devices exclusive worldwide marketing and distribution rights for BreastCheck.
-
Odyssey Health extends maturity dates on convertible notes with insiders and LGH Investments
Amended notes with two directors and two officers (each $25,000) to mature Jan 31, 2027.
-
Odyssey Health secures up to $25M financing facility and 9-year service contract
Entered Maintenance Agreement with Mast Hill Fund; issued $2.262M convertible note at 10% interest due Nov 2026.
-
Odyssey Health signs exclusive worldwide sub-license for BreastCheck non-invasive breast test
Sub-license grants exclusive global marketing and distribution rights for BreastCheck, a 15-minute at-home test.
-
Enters Amendment No. 6 with Mast Hill Fund L.P. on $870,000 promissory note originally issued Dec 13, 2022.
-
Odyssey Health enters $100K promissory note with 18% interest, issues 100K-share warrant at $0.10
Note for $100,000 from Peter D'Arruda, due Sept. 30, 2026, with 18% annual interest.
-
Odyssey Health extends maturity of $1.05M convertible note to Jan 31, 2026
Convertible promissory note dated April 5, 2021, principal $1,050,000.
-
Odyssey Health closes $220K convertible note and warrant financing with Mast Hill Fund
Principal $220,000, one-year, 10% note convertible at 85% of 10-day VWAP; default rate 16%.
-
Odyssey Health extends $300K promissory note maturity to Jan 31, 2026
Amendment No. 1 extends maturity of $300,000 note from Aug 14, 2024 to Jan 31, 2026.
-
Odyssey Health extends convertible note maturity to Jan 31, 2026
Amendment No. 4 extends maturity of Feb 13, 2024 convertible note with Jonathan Lutz to January 31, 2026.
-
Odyssey Health extends maturity of promissory notes with officers/directors to Jan 31, 2026
Four Promissory Note Amendments No. 11 extend maturity date from prior to January 31, 2026.
-
Odyssey Health enters $25M equity purchase agreement with Mast Hill Fund
Entered $25M equity purchase agreement with Mast Hill Fund; shares sold at 97% of VWAP discount.
-
Odyssey Health extends promissory note maturity to Oct 10, 2025 with Mast Hill Fund
Maturity date of $870,000 promissory note extended to October 10, 2025.
-
FINRA approves Odyssey Health name change, effective May 27
FINRA approved name change from Odyssey Group International to Odyssey Health on OTC Markets, effective May 27, 2025.
-
Odyssey Health extends maturity dates on two promissory notes to July 31, 2025
Extended Jon Lutz promissory note maturity to July 31, 2025 (Amendment No. 3).
-
Odyssey Health extends maturity of insider promissory notes to July 31, 2025
Four promissory notes held by two directors and two officers amended for tenth time.
-
Odyssey Health receives $300,000 via 18% promissory note; issues warrant for 300k shares
Received $300,000 from accredited investor Peter J. D'Arruda on August 22, 2024, per promissory note dated August 14, 2024.
-
Odyssey Health extends convertible note maturity to June 30, 2024, adds $60K principal
Amended convertible promissory note with LGH Investments; maturity extended to June 30, 2024.
-
Sold drug candidates for mild traumatic brain injury and Niemann Pick Disease Type C, plus proprietary powder formulation and nasal delivery device.
-
Odyssey Health shareholders approve asset sale to Oragenics for $1M cash + 8M shares
Stockholders voted 45,032,700 for, 382,191 against the asset sale to Oragenics.
-
Odyssey Health shareholders approve asset sale of neurological drug therapies to Oragenics
Approved asset purchase agreement of neurological drug therapies and technologies to Oragenics, Inc.
-
Extended maturity of $25,000 promissory notes from two officers and two directors to January 31, 2024.
-
Director John Gandolfo resigns from Odyssey Health board effective October 5, 2023
John Gandolfo resigned as director on October 5, 2023.
-
Odyssey Health sells neurological drug pipeline to Oragenics for $1M and 8M preferred shares
Oragenics to acquire Odyssey's assets including concussion drug ONP-002 and NPC candidate; cash payment of $1M and 8M Series F Preferred Shares.
-
Odyssey Health issues $500K convertible note with warrants tied to Spinco IPO
Note purchase agreement with two accredited investors for $500,000 principal amount.
-
Extended maturity on five promissory notes from directors/officers to Oct 31, 2023; conversion price $0.12/share.
-
Odyssey Health signs non-binding LOI to merge with Speranza Therapeutics in all-stock deal
Speranza's lead product ST Genesis is a wearable device for opioid withdrawal, FDA cleared, 93% response rate, targets $1.4B market.
-
Odyssey Health extends convertible note maturity to June 30, 2023; adds $20K principal
Extended maturity of $1.05M convertible note held by LGH Investments to June 30, 2023; $20K added to principal.
-
Odyssey Health shareholders approve reverse stock split; Conroy resigns from board
Reverse stock split of common stock approved: 39.8M for, 4.4M against, 39k abstain.
-
Director Jeffrey Conroy resigns from Odyssey Health board effective Jan 4, 2023
Jeffrey Conroy resigned as director effective January 4, 2023.
-
Amendment No. 4 with LGH extends $1.05M note maturity to March 31, 2023; adds $50K to principal, paydown $35K.
-
Odyssey Health provides update on concussion drug program; Phase I trial completed, safety shown
Completed FDA-required Phase I human clinical trial; drug safe, well tolerated, no accumulation over 10 days.
-
Odyssey Health acquires option to purchase PRV-001 patents from Prevacus for 1M shares
Option to buy 100% of worldwide patents to PRV-001 and an Enantiomer from Prevacus.
-
Odyssey Health receives $313,709 R&D rebate from Australian government for Phase I trial work
Rebate of $313,709 ($468,727 AUD) received on November 18, 2022.
-
Odyssey Health hires CCO and COO for NeuroPharma; salaries contingent on $5M fundraising
Erik Emerson named CCO and Greg Gironda named COO of Odyssey NeuroPharma, effective Nov 1, 2022.
-
Odyssey Health files patent for intranasal brain-drug device; Phase I study successful
Filed US/global patent for breath-propelled intranasal brain-drug delivery device (Nasal Device).
-
Dissolved sports advisory board to eliminate distraction and maintain focus on drug development.
-
Odyssey Health extends convertible note maturity to Dec 31, 2022; adds $115K principal
Amendment with LGH Investments extends $1.05M convertible note maturity to Dec 31, 2022; principal increased by $115,000.
-
Odyssey Health completes Phase I trial for concussion drug PRV-002; drug safe and well-tolerated
Phase I SAD and MAD trial enrolled 40 healthy volunteers; drug was safe and well-tolerated with no severe adverse events.
-
Odyssey Health receives 8M shares back from shareholder; shares retired to treasury
Shareholder returned 8 million common stock shares to the company on September 15, 2022.
-
Odyssey Health reports positive Phase I MAD safety data for concussion drug PRV-002
PRV-002 was safe and well tolerated in 8 healthy volunteers given five daily doses.
-
Shareholder returned 7,370,000 shares; received by transfer agent on July 27, 2022.
-
Odyssey Health completes Phase I SAD trial for concussion drug PRV-002; moving to MAD phase
Phase I Single Ascending Dosing (SAD) completed with three cohorts; drug PRV-002 safe and well tolerated, no severe adverse events.
-
Odyssey Health closes second closing of private placement; gross proceeds $415,650
Second closing issued 1,781,358 Units at $0.35/Unit for gross proceeds of $415,650.20.
-
Odyssey Health reports positive initial Phase I results for concussion drug PRV-002
First group of 5 healthy subjects dosed with PRV-002 showed safety and tolerability; no serious adverse events.
-
Odyssey Health closes initial $1.0M private placement of 4.3M units at $0.35
First closing on April 14, 2022, issued 4,306,200 units at $0.35 each; each unit equals one share and one-half warrant.
-
Odyssey Health adds Vice Admiral (r) Timothy Szymanski to Military Advisory Board
Vice Admiral (r) Szymanski served 36 years as Navy SEAL, most recently Deputy Commander USSOCOM.
-
Odyssey extends convertible note maturity to March 2023, principal increased by $25K
Extended maturity of $250K convertible note to March 1, 2023; added $25K to principal balance.
Executive changes
Departed
Jeffrey Conroy
Director
ODYY ·
Odyssey Health, Inc.
Effective January 4, 2023, Jeffrey Conroy resigned as a director of Odyssey Health, Inc.
Appointed
Greg Gironda
Chief Operations Officer
ODYY ·
Odyssey Health, Inc.
On November 1, 2022, the Company and Mr. Gironda entered into an employment agreement (the “Agreement”) for a one (1) year term as Chief Operations Officer.
Appointed
Erik Emerson
Chief Commercial Officer
ODYY ·
Odyssey Health, Inc.
On November 1, 2022, the Company and Mr. Emerson entered into an employment agreement (the “Agreement”) for a one (1) year term as Chief Commercial Officer.
Materiality & sentiment trend
Max materiality 0.75 · Median 0.55 · Most common event debt